Bradley McGregor, MD, discusses the ongoing COSMIC-313 trial of cabozantinib, ipilimumab, and nivolumab in patients with renal cell carcinoma.
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the ongoing COSMIC-313 trial (NCT03937219) of cabozantinib (Cabometyx), ipilimumab (Yervoy), and nivolumab (Opdivo) in patients with renal cell carcinoma (RCC).
COSMIC-313 is a randomized trial of this combination compared with nivolumab and ipilimumab. In this setting, there are many different VEGF inhibitors and immune-oncology (IO) combinations with slightly different toxicity profiles and different drugs. There are also IO-IO combinations—for these, it seems like there are a group of patients who have a durable response and are able to go off of therapy, according to McGregor. It is uncertain if this response will be seen with VEGF and IO combinations since those data are still maturing. With IO-IO combinations for patients with RCC, over 20% have progressive disease as their best response.
McGregor says the hope with COSMIC-313 is that the triplet combination of nivolumab and ipilimumab with cabozantinib will be able to overcome the progressive disease as best response for these patients. He also hopes that this combination will maintain a point where patients can continue on therapy and have durability of their response.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More